Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
SYK · NYSE · Healthcare
Fundamental quality
79
out of 100
Stryker Corp earns a fundamental-quality score of 79 out of 100, profiling it as a company with solid fundamentals. Its score rests mainly on its financial strength (net debt 1.62× EBITDA). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Stryker is one of the world's largest medical-device makers. It sells implants (hips, knees), surgical equipment, robots for orthopedic surgery and hospital supplies. Its business grows with an aging population and rising surgery volumes.
EPS growth: 16.3% · Revenue growth: 11.3%
Net margin: 14.4% · ROE: 15.5% · ROIC: 11.3%
Net debt/EBITDA: 1.62x · FCF: 18.2%
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +1 for dividend strength: 7 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength, and here its pillars hold up evenly.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 14,351 | 1,599 | 2,790 | 11,048 |
| 2021 | 17,108 | 1,994 | 2,738 | 9,535 |
| 2022 | 18,449 | 2,358 | 2,036 | 11,204 |
| 2023 | 20,498 | 3,165 | 3,136 | 10,024 |
| 2024 | 22,595 | 2,993 | 3,487 | 9,945 |
| 2025 | 25,116 | 3,246 | 4,283 | 11,848 |
Between 2020 and 2025, revenue went from $14,351M to $25,116M (+75%) and net income went from $1,599M to $3,246M (+103%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$1.57
per share, yearly
39.6% of earnings
Payout
7 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Stryker Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Stryker Corp a good company to invest in?
In terms of business quality, Stryker Corp scores 79 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Stryker Corp a profitable company?
Yes. Stryker Corp shows a net margin of 14.4% and an ROE of 15.5%, a sign of a profitable business.
Does Stryker Corp have a lot of debt?
A moderate level: its net debt is 1.62 times its EBITDA.
Is Stryker Corp growing?
Its revenue has grown 11.3% annualized in recent years and its earnings per share 16.3%, and without interruption since 2020.
Does Stryker Corp generate cash?
Yes. It converts about 18.2% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Thermo Fisher Scientific (TMO) · Abbott Laboratories (ABT) · Intuitive Surgical (ISRG) · Pfizer (PFE) · Amgen (AMGN) · Gilead Sciences (GILD) · see more →
The best Healthcare stocks by our model →
Who's behind the methodology and model · how the score is computed
Data: see Stryker Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.